As National Party Congress concludes, China’s FDA seeks to write widely-anticipated drug reforms into law
In a bid to move Chinese drug industry regulations closer to the US/European model, China’s FDA yesterday proposed significant changes to the nation’s Drug Administration Act.
The widely expected move comes on the heels of instructions given two weeks ago by the reigning State Council, China’s cabinet, just prior to the 19th Communist Party Congress meeting this past week. It confirmed Xi Jingping as the most powerful Chinese leader since Mao and Deng, enshrining his personal brand of socialism “with Chinese characteristics for a new era” into official dogma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.